106
Participants
Start Date
January 31, 2016
Primary Completion Date
January 31, 2020
Study Completion Date
January 31, 2020
Lacosamide
"* Pharmaceutical Form: Oral tablets~* Concentration: 50 mg~* Route of Administration: Oral administration"
Sp1042 805, Blagoevgrad
Sp1042 807, Pazardzhik
Sp1042 811, Sofia
Sp1042 205, Helsinki
Sp1042 207, Kuopio
Sp1042 236, Nancy
Sp1042 263, Altenburg
Sp1042 265, Bad Neustadt an der Saale
Sp1042 269, Leipzig
Sp1042 256, Marburg
Sp1042 259, Osnabrück
Sp1042 831, Asaka
Sp1042 834, Kagoshima
Sp1042 844, Kamakura
Sp1042 835, Nagoya
Sp1042 837, Okayama
Sp1042 847, Sapporo
Sp1042 751, Riga
Sp1042 547, San Luis Potosí City
Sp1042 672, Pasig
Sp1042 676, Quezon
Sp1042 340, Katowice
Sp1042 342, Lublin
Sp1042 343, Warsaw
Sp1042 576, Bucharest
Sp1042 570, Iași
Sp1042 572, Târgu Mureş
Sp1042 387, Kazan'
Sp1042 389, Kazan'
Sp1042 401, Moscow
Sp1042 392, Novosibirsk
Sp1042 397, Saint Petersburg
Sp1042 400, Saint Petersburg
Sp1042 521, Daegu
Sp1042 518, Daejeon
Sp1042 517, Seoul
Sp1042 519, Seoul
Sp1042 440, Gothenburg
Sp1042 442, Linköping
Sp1042 438, Stockholm
Sp1042 651, Aarau
Sp1042 654, Biel
Sp1042 653, Lugano
Sp1042 622, Chernihiv
Sp1042 626, Kharkiv
Sp1042 625, Odesa
Collaborators (1)
Parexel
INDUSTRY
UCB Biopharma S.P.R.L.
INDUSTRY